Drug Shortages and Supply Chain
Drug shortages are a persistent patient safety crisis: thousands of medicines appear on shortage lists each year, with sterile injectable generics disproportionately affected. This guide covers root causes, FDA management tools, clinical strategies, and policy reform.
Why do drug shortages occur? Drug shortages result from the convergence of multiple systemic vulnerabilities in the pharmaceutical supply chain. Manufacturing quality events — including FDA 483 observations, Warning Letters, and facility remediations — account for the largest share of shortage root causes. When a sterile injectable manufacturing plant fails a cGMP inspection, the resulting shutdown can remove 30–50% of US supply for that product overnight. API (active pharmaceutical ingredient) sourcing concentration compounds the problem: approximately 60–80% of APIs for US generic drugs are manufactured in India or China, creating single-country dependency risks from regulatory shutdowns, trade disruptions, or natural disasters. Demand surges from unexpected clinical needs (pandemic-related drug use, explosive off-label adoption of GLP-1 agonists) can overwhelm existing production capacity within weeks. Finally, market failures drive manufacturer exits: generic drug prices are often below the cost of maintaining quality manufacturing, particularly for capital-intensive sterile injectables, causing manufacturers to discontinue products and creating single-supplier markets. The FDA drug shortage FAQ and ASHP shortage statistics provide comprehensive data on these root causes.
The impact of drug shortages extends beyond treatment delays to include increased medication errors, use of less effective therapeutic alternatives, and direct patient harm. The WHO has identified drug shortages as a global health security issue, while the ISMP documents the patient safety consequences of shortage-driven substitutions and workarounds.
What is a drug shortage?
A drug shortage exists when the total supply of all clinically interchangeable versions of a regulated drug product is insufficient to meet current or projected demand at the patient level. The FDA drug shortage database ↗ currently lists over 100 active shortages at any given time; ASHP's database often tracks 300–400 active shortages simultaneously, including products FDA has determined are not in shortage under its narrower definition.
The consequences range from treatment delays and suboptimal substitutions to medication errors — see our medication errors guide — and direct patient harm. The FDA defines shortage officially as "a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug."
Root causes of drug shortages
Multiple intersecting factors drive pharmaceutical supply chain fragility:
FDA 483 observations, Warning Letters, and consent decrees force facility shutdowns or output reductions. Sterile injectable plants are most vulnerable. See our drug recalls guide for the cGMP framework.
60–80% of active pharmaceutical ingredients (APIs) for US generic drugs are manufactured in India or China. A single facility fire, flood, or regulatory closure can affect dozens of finished drug products globally.
Unexpected demand spikes — new FDA approvals, off-label adoption (e.g. GLP-1 agonists for weight loss), pandemic-related use (albuterol, sedatives) — can overwhelm existing production capacity within weeks.
Generic drug prices are often below the cost of maintaining manufacturing quality for specialised products. Low margins cause manufacturers to exit products or reduce investment in facility maintenance, creating single-supplier situations.
Most shortage-prone drug categories
Injectable sterile generics account for the majority of clinical-impact shortages. These drugs require specialised aseptic manufacturing, have thin profit margins, and are often produced by only 1–3 manufacturers in the US market.
| Category | Examples | Risk factors |
|---|---|---|
| Injectable oncology agents | Carboplatin, methotrexate, vincristine, etoposide | Few manufacturers, low margin, sterile |
| Critical care injectables | Norepinephrine, vasopressin, propofol, fentanyl | Surge demand, sterile, narrow TI |
| Antibiotics (IV) | Ceftazidime-avibactam, aztreonam-avibactam, piperacillin-tazobactam | Rising AMR demand, limited alternatives |
| Electrolytes/fluids | IV sodium bicarbonate, potassium phosphate, IV saline | Hurricane/disaster supply disruption |
For the most clinically critical current shortage (October 2026), see: ceftazidime-avibactam and aztreonam-avibactam shortage.
Clinical management of drug shortages
Hospital pharmacy and therapeutics (P&T) committees, antimicrobial stewardship programmes (ASPs), and clinical pharmacists are the front-line responders to drug shortages.
- Therapeutic substitution: identify a clinically equivalent alternative within the same drug class or mechanism. Pharmacokinetic principles are central — see pharmacokinetics basics and bioequivalence for substitution principles
- Dose rounding: round doses to available vial sizes to eliminate partial-vial waste and extend supply. Most oncology agents permit ±5–10% rounding without clinical impact
- Prioritisation protocols: allocate shortage drugs to the most critical indications (e.g. curative vs palliative chemotherapy; empiric vs definitive antibiotics)
- Extended stability: pharmacy validation of beyond-use dates for shortage products, in accordance with USP <797> ↗ compounding standards
- Communication: timely prescriber notification via P&T communications, EHR alert systems, and formulary management tools